Shots:

• The companies will evaluate SpringWorks’ Nirogacestat (GSI) in combination with Janssen’s Teclistamab (Ab targeting BCMA and CD3) in patients with r/r MM. The companies anticipate commencing the study by early 2021
• Janssen to sponsor and conduct a P-I study assessing the safety- tolerability- and preliminary efficacy of the combination- and will assume all costs associated with the study- other than expenses related to the manufacturing of nirogacestat
• SpringWorks will form a joint oversight committee with Janssen and is currently conducting a global P-III DeFi trial assessing nirogacestat vs PBO in adults with progressing desmoid tumors. Additionally- SpringWorks has entered two other clinical collaborations to evaluate nirogacestat in combination with GSK’s Blenrep (belantamab mafodotin-blmf) and with Allogene’s ALLO-715

­ Ref: PRNewswire | Image: Janssen